HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Systemic bevacizumab for simultaneous treatment of cancer and choroidal neovascularisation.

Abstract
A 47-year-old woman with a medical history of pseudoxanthoma elasticum and associated choroidal neovascularisation that was successfully managed with intravitreal bevacizumab injections developed non-squamous non-small cell lung carcinoma. The patient's oncological medication regimen included systemic bevacizumab. During the 22 months that the patient received systemic bevacizumab for management of her malignancy, intravitreal bevacizumab injections were held and the patient's visual acuity remained stable and the subretinal space was free of fluid leakage.
AuthorsNorman Saffra, Benjamin Reinherz
JournalBMJ case reports (BMJ Case Rep) Vol. 2014 (May 13 2014) ISSN: 1757-790X [Electronic] England
PMID24825559 (Publication Type: Case Reports, Journal Article)
Copyright2014 BMJ Publishing Group Ltd.
Chemical References
  • Angiogenesis Inhibitors
  • Antibodies, Monoclonal, Humanized
  • Bevacizumab
Topics
  • Angiogenesis Inhibitors (administration & dosage)
  • Antibodies, Monoclonal, Humanized (administration & dosage)
  • Bevacizumab
  • Carcinoma, Non-Small-Cell Lung (complications, drug therapy)
  • Choroidal Neovascularization (complications, drug therapy)
  • Drug Administration Routes
  • Female
  • Humans
  • Intravitreal Injections
  • Lung Neoplasms (complications, drug therapy)
  • Middle Aged
  • Pseudoxanthoma Elasticum (complications)
  • Tomography, Optical Coherence
  • Treatment Outcome

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: